The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the Tobevibart + Elebsiran combination from Vir Biotechnology, highlight the industry's growing focus on this high unmet need, as developers continue to advance innovative treatment approaches for this challenging disease.

LAS VEGAS, Jan. 29, 2026 /PRNewswire/ -- DelveInsight's Chronic Hepatitis D Market Insights report includes a comprehensive understanding of current treatment practices, chronic hepatitis D emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

Chronic Hepatitis D Market Summary

• The market size for chronic hepatitis D in the leading markets is expected to grow significantly by 2034.
• The United States accounted for the highest chronic hepatitis D treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• Over 12 million people globally are chronically infected with the hepatitis D virus, which is recognized as the most severe form of viral hepatitis.
• Leading chronic hepatitis D companies developing emerging therapies, such as Bluejay Therapeutics, Vir Biotechnology, and others, are developing new therapy for chronic hepatitis D that can be available in the chronic hepatitis D market in the coming years. 
• The promising chronic hepatitis D therapies in clinical trials include Brelovitug (BJT-778), Tobevibart + Elebsiran, and others.

Discover the opportunities and challenges in the hepatitis D market @ https://www.delveinsight.com/sample-request/chronic-hepatitis-delta-virus-infection-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Chronic Hepatitis D Market 

• Rising Global Disease Burden: Increased prevalence of HDV infection, especially in regions with high hepatitis B (HBV) incidence, such as parts of Africa, the Mediterranean, Eastern Europe, and Asia-Pacific.
• Growing Awareness and Diagnosis: Improved screening and diagnostic capabilities are enabling earlier and more accurate detection of HDV in HBV-infected patients.
• Multi-Targeted Strategies in HDV Management: Brelovitug from Bluejay Therapeutics, along with Tobevibart plus Elebsiran from Vir Biotechnology, are emerging as promising next-generation treatments for chronic HDV. By addressing viral entry and replication through complementary approaches, these therapies signal a shift toward multi-targeted strategies that may offer greater effectiveness than traditional interferon-based treatments.

Chronic Hepatitis D Market Analysis

• Testing for the hepatitis D virus remains limited despite its clinical importance. Lack of standardized HDV RNA assays hampers accurate detection of active infection and monitoring of treatment response. This contributes to underdiagnosis and delays in timely clinical management.
• Pegylated interferon alpha (PEG-IFNα) was historically the only available therapy for chronic HDV.
• Clinical utility is limited due to modest efficacy, high rates of side effects, and multiple contraindications. Few patients achieve a complete virological response, and relapses are common after treatment ends.
• The treatment landscape is evolving, with new therapies showing promising outcomes. In 2023, bulevirtide, a once-daily subcutaneous entry inhibitor, was approved by the European Medicines Agency for adults with chronic HDV.
• Ongoing multicenter studies are evaluating optimal dosing, treatment duration, and potential combination strategies with PEG-IFNα.
• Nucleoside analogues used for hepatitis B management show no direct antiviral effect on HDV. They remain important for controlling concurrent HBV infection in co-infected patients.

To know more about what is the impact of new therapies on market growth, visit @ Approved Chronic Hepatitis D Drugs

Chronic Hepatitis D Competitive Landscape

Brelovitug (Bluejay Therapeutics) and the Tobevibart + Elebsiran (Vir Biotechnology) represent promising next-generation therapies for chronic HDV. Targeting viral entry and replication through complementary mechanisms, they reflect a shift toward multi-targeted, more effective treatment strategies beyond interferon-based options.

Bluejay Therapeutics' Brelovitug (BJT-778) is a highly potent, fully human IgG1 monoclonal antibody that specifically targets the hepatitis B virus surface antigen (anti-HBsAg) and exhibits pan-genotypic activity. It is under investigation as a potential standalone therapy for adults with chronic hepatitis D and as a cornerstone of combination strategies aimed at achieving a functional cure for chronic hepatitis B. Brelovitug works by neutralizing and clearing hepatitis B and D virions and depleting HBsAg-containing subviral particles. Additionally, it has demonstrated potential as a powerful immunomodulator.

Tobevibart is an investigational monoclonal antibody administered subcutaneously that targets the hepatitis B surface antigen to prevent hepatitis B and D viruses from entering liver cells while reducing circulating viral particles. It incorporates extended half-life technologies and is being clinically evaluated for chronic hepatitis B and D.

Elebsiran is a subcutaneous investigational siRNA therapy designed to degrade hepatitis B virus RNA, thereby reducing surface antigen production. It has shown potential antiviral activity against both hepatitis B and D viruses and is being developed through a collaboration between Vir Biotechnology and Alnylam Pharmaceuticals.

The anticipated launch of these emerging therapies are poised to transform the chronic hepatitis D market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic hepatitis D market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about what are the leading HDV treatments and pipeline therapies @ Chronic Hepatitis D Clinical Trials 

What is Chronic Hepatitis D?

Chronic hepatitis D (CHD) is a severe, progressive liver disease caused by persistent infection with the hepatitis D virus (HDV), a defective RNA virus that can only replicate in the presence of the hepatitis B virus (HBV). It occurs either as a coinfection with HBV or, more commonly in chronic cases, as a superinfection in individuals already living with chronic hepatitis B. CHD is considered the most aggressive form of viral hepatitis, characterized by faster disease progression and a significantly higher risk of advanced liver complications, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite affecting a relatively smaller patient population compared with other viral hepatitides, chronic hepatitis D represents a major unmet medical need due to limited therapeutic options and historically poor clinical outcomes.

Chronic Hepatitis D Epidemiology Segmentation

The chronic hepatitis D epidemiology section provides insights into the historical and current chronic hepatitis D patient pool and forecasted trends for the leading markets. In the US, up to 2.4 million people are hepatitis B surface antigen (HBsAg)-positive. Among them, 3–6% test positive for HDV antibodies, and 50–70% of those have active HDV infection based on RNA testing, translating to an estimated 70,000 to 150,000 active HDV cases in the US.

The chronic hepatitis D market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Total Prevalent Cases of Chronic Hepatitis D Virus
• Total Diagnosed Prevalent Cases of Chronic Hepatitis D Virus
• Gender-specific Cases of Chronic Hepatitis D Virus
• Age-specific Cases of Chronic Hepatitis D Virus
• Treated Cases of Chronic Hepatitis D Virus

Scope of the Chronic Hepatitis D Market Report

• Therapeutic Assessment: Chronic Hepatitis D current marketed and emerging therapies
• Chronic Hepatitis D Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Hepatitis D Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Chronic Hepatitis D Market Access and Reimbursement

Download the report to understand can hepatitis B vaccination prevent hepatitis D @ Chronic Hepatitis D Vaccine

Table of Contents

Related Reports

Chronic Hepatitis D Clinical Trial Analysis

Chronic Hepatitis D Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHD companies, including Eiger BioPharmaceuticals, Huahui Health, Vir Biotechnology, Shanghai HEP Pharmaceutical, Janssen Research & Development, Bluejay Therapeutics, Assembly Biosciences, among others.

Chronic Hepatitis B Market

Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CHB companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others.

Hepatitis A Market

Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, among others.

Hepatitis C Market

Hepatitis C Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis C companies, including AbbVie, Gilead Sciences, Atea Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com  
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/chronic-hepatitis-d-market-poised-for-significant-growth-during-the-forecast-period-20252034-as-emerging-therapies-drive-optimism--delveinsight-302673525.html

SOURCE DelveInsight Business Research, LLP